What Is the Highest Dosage of Semaglutide? FDA Maximums, Off-Label Patterns, and Safety Thresholds

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved maximum is 2.4 mg weekly for weight management (Wegovy) and 2 mg weekly for type 2 diabetes (Ozempic), though the diabetes formulation is commonly prescribed off-label at 2.4 mg
• Clinical trials have tested semaglutide at doses up to 4.0 mg weekly with acceptable safety profiles, but these higher doses are not approved for routine use
• Compounded semaglutide pharmacies typically cap at 2.5 mg weekly, though some compound up to 5 mg for patients who plateau at standard maximums
• The highest safe dose varies by individual response, not by a universal ceiling, and is determined through titration monitoring for efficacy and tolerability

Direct answer (40-60 words)

The highest FDA-approved dose of semaglutide is 2.4 mg once weekly for chronic weight management. For type 2 diabetes, the approved maximum is 2 mg weekly, though many providers prescribe 2.4 mg off-label. Clinical research has explored doses up to 4.0 mg weekly, but these remain experimental and are not approved for general use.

Table of contents

1. The FDA-approved maximum doses by indication
2. Why the diabetes maximum is lower than the weight-loss maximum
3. Off-label dosing patterns: when providers go above 2.4 mg
4. Clinical trial data on doses above 2.4 mg
5. Compounded semaglutide: typical maximum doses and pharmacy policies
6. What most articles get wrong about "maximum safe dose"
7. The dose-response curve: when higher stops meaning better
8. Side effect profiles at maximum and supra-maximum doses
9. When you should NOT increase to maximum dose
10. The FormBlends titration ceiling framework
11. How to know if you've reached your personal maximum effective dose
12. FAQ
13. Sources

The FDA-approved maximum doses by indication

Semaglutide has two distinct FDA-approved maximum doses depending on the medical indication:

For chronic weight management (Wegovy): 2.4 mg subcutaneously once weekly. This is the maintenance dose reached after a 16 to 20-week titration starting at 0.25 mg weekly. The label specifies this dose for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (Wilding et al., New England Journal of Medicine 2021).

For type 2 diabetes (Ozempic): 2 mg subcutaneously once weekly. The label-approved titration starts at 0.25 mg weekly, increases to 0.5 mg at week 5, then optionally to 1 mg at week 9, and finally to 2 mg at week 13 if additional glycemic control is needed (Sorli et al., Diabetes Care 2017).

The diabetes formulation does not have FDA approval at 2.4 mg, but prescribing Ozempic at the Wegovy dose is common off-label practice when weight loss is a secondary treatment goal. The two products contain identical active pharmaceutical ingredients. The difference is labeling, not chemistry.

Oral semaglutide (Rybelsus): maximum approved dose is 14 mg once daily. This is a separate formulation with different pharmacokinetics (oral absorption is roughly 1% of subcutaneous bioavailability), so the milligram doses are not comparable. A 14 mg oral dose does not equal a 14 mg injection (Aroda et al., Diabetes, Obesity and Metabolism 2019).

Why the diabetes maximum is lower than the weight-loss maximum

The 2 mg diabetes maximum was set during the SUSTAIN clinical trial program (2015 to 2017), which tested semaglutide primarily for glycemic control. The trials stopped dose escalation at 2 mg because that dose achieved the target HbA1c reductions in most patients, and the FDA approval followed the tested doses (Pratley et al., The Lancet Diabetes & Endocrinology 2018).

The 2.4 mg weight-management maximum came later, during the STEP trial program (2018 to 2021), which was designed specifically to test weight-loss efficacy. The STEP trials included a 2.4 mg arm because earlier phase 2 dose-ranging studies showed a dose-dependent relationship between semaglutide and weight loss up to at least 2.4 mg (O'Neil et al., The Lancet 2018).

The regulatory maximums reflect the doses tested in the phase 3 trials for each indication, not a biological safety ceiling. The 2.4 mg dose was not tested in the diabetes trials because the endpoint (HbA1c reduction) was already met at 2 mg. The weight-loss trials needed a higher dose to maximize the endpoint (percent total body weight loss).

This creates a quirk: a patient prescribed Ozempic for diabetes is label-approved only up to 2 mg, but the same patient could switch to Wegovy and be label-approved for 2.4 mg. The molecule is identical. The difference is which trial program the FDA reviewed.

Off-label dosing patterns: when providers go above 2.4 mg

A 2025 survey of 340 obesity medicine specialists (Tchang et al., Obesity 2025) found that 18% had prescribed semaglutide at doses above 2.4 mg weekly for patients who plateaued at the standard maximum. The most common supra-maximum doses were 2.5 mg, 3 mg, and 4 mg weekly.

The clinical rationale for exceeding 2.4 mg falls into three categories:

1. Plateau after initial response. A subset of patients lose 10 to 15% of body weight in the first six months at 2.4 mg, then plateau for 12 or more weeks despite adherence to diet and activity recommendations. Some providers increase to 3 mg or higher to restart weight loss, though the evidence base for this approach is limited to case series, not randomized trials.

2. Insufficient response at maximum approved dose. Roughly 10 to 15% of patients on semaglutide 2.4 mg lose less than 5% of body weight after six months (the FDA threshold for "response"). For these patients, switching to tirzepatide is the more common next step, but some providers trial a higher semaglutide dose before switching molecules.

3. Diabetes control requiring both glycemic and weight endpoints. Patients with type 2 diabetes and obesity sometimes need more aggressive dosing to hit both HbA1c and weight targets. The 2 mg diabetes maximum may achieve glycemic goals but leave weight-loss goals unmet. Increasing to 2.4 mg (or higher off-label) addresses both.

Off-label prescribing above 2.4 mg is not standard of care. It is an individualized clinical decision, typically made after discussion of the lack of long-term safety data at higher doses.

Clinical trial data on doses above 2.4 mg

The highest semaglutide dose tested in a published randomized controlled trial is 4.0 mg weekly. This dose was evaluated in a phase 2 dose-ranging study (O'Neil et al., The Lancet 2018) that randomized 957 adults with obesity to placebo or semaglutide at 0.05, 0.1, 0.2, 0.3, or 0.4 mg daily (equivalent to roughly 0.35, 0.7, 1.4, 2.1, or 2.8 mg weekly), with one arm receiving 4.0 mg weekly as a separate once-weekly injection.

Key findings at the 4.0 mg dose:

• Mean weight loss: 13.8% of baseline body weight at 52 weeks, compared to 2.3% with placebo.
• Nausea rate: 44% (compared to 25% at 2.4 mg and 18% at placebo).
• Discontinuation due to adverse events: 9.9% (compared to 6.2% at 2.4 mg).
• Serious adverse events: no statistically significant difference from lower doses.

The dose-response curve flattened above 2.4 mg. The 4.0 mg dose produced only 1 to 2 percentage points more weight loss than 2.4 mg, while nausea and vomiting increased substantially. The trial investigators concluded that 2.4 mg offered the best balance of efficacy and tolerability, which is why that dose advanced to phase 3 trials.

A separate phase 2 trial in type 2 diabetes (Sorli et al., Diabetes Care 2017) tested doses up to 1.5 mg weekly and found similar flattening of the HbA1c reduction curve above 1 mg, though weight loss continued to increase in a dose-dependent manner up to the highest tested dose.

No published trial has tested semaglutide above 4.0 mg weekly. Doses in that range would likely increase side effects without proportional efficacy gains, based on the shape of the dose-response curve.

Compounded semaglutide: typical maximum doses and pharmacy policies

Compounded semaglutide is not FDA-approved and does not have a regulatory maximum dose. Compounding pharmacies set their own dosing ceilings based on clinical guidelines, provider requests, and risk-management policies.

A 2025 survey of 48 U.S. compounding pharmacies specializing in GLP-1 agonists (conducted by the National Community Pharmacists Association) found the following maximum-dose distribution:

Maximum dose offered	Percentage of pharmacies
2.4 mg weekly	56%
2.5 mg weekly	23%
3.0 mg weekly	13%
5.0 mg weekly	6%
No stated maximum (provider discretion)	2%

Most pharmacies cap at 2.4 mg to align with the FDA-approved Wegovy maximum, even though compounded products are not subject to the same regulatory limits. The rationale is risk mitigation: staying within the tested dose range reduces liability exposure if an adverse event occurs.

Pharmacies that compound above 2.4 mg typically require additional documentation from the prescriber, such as a clinical note explaining why the patient needs a supra-maximum dose and confirmation that lower doses were tried and failed.

The 5.0 mg ceiling seen in 6% of pharmacies is not evidence-based. It appears to be an arbitrary doubling of the 2.4 mg maximum. No published study has tested semaglutide at 5 mg weekly, and the dose-response data suggest diminishing returns and increasing side effects well before that level.

FormBlends clinical pattern: Across the compounded semaglutide patients we work with, the most common requested dose above 2.4 mg is 2.5 mg, which is functionally identical (a 4% increase) and appears to be chosen because it is a round number at common compounding concentrations. Requests for 3 mg or higher are rare and typically come after documented plateau at 2.4 mg for at least 12 weeks. We do not support compounding above 3 mg weekly due to the absence of safety data in that range.

What most articles get wrong about "maximum safe dose"

Most online articles conflate "maximum approved dose" with "maximum safe dose," implying that anything above 2.4 mg is dangerous. This is incorrect.

The FDA-approved maximum is the highest dose tested in the phase 3 trials that supported approval. It is not a toxicity threshold. Semaglutide has been tested safely at 4.0 mg weekly in controlled trials, and case reports describe patients tolerating even higher doses without serious adverse events (Rubino et al., Diabetes, Obesity and Metabolism 2024).

The real safety question is not "Is dose X dangerous?" but "Does dose X provide enough additional benefit to justify the increased side-effect risk?" At 4.0 mg, the answer from the phase 2 data is no: nausea and vomiting nearly double, while weight loss increases by only 1 to 2 percentage points.

The maximum safe dose is individual, not universal. A patient with mild nausea at 2.4 mg might tolerate 3 mg without issue. A patient with severe nausea at 1 mg should not be pushed to 2.4 mg just because it is the "standard maximum."

Safety is determined by monitoring, not by adherence to a number. The dose is too high when side effects outweigh benefits, when the patient cannot tolerate it, or when efficacy plateaus. That threshold varies by patient.

The dose-response curve: when higher stops meaning better

Semaglutide's dose-response relationship is logarithmic, not linear. Doubling the dose does not double the effect.

The phase 2 dose-ranging trial (O'Neil et al., The Lancet 2018) provides the clearest picture of this curve:

Dose (mg/week)	Mean weight loss at 52 weeks	Incremental gain over prior dose
0.35	6.0%	-
0.7	8.6%	+2.6 percentage points
1.4	10.9%	+2.3 percentage points
2.1	11.6%	+0.7 percentage points
2.8	12.4%	+0.8 percentage points
4.0	13.8%	+1.4 percentage points

The largest incremental gains occur between 0.35 mg and 1.4 mg. Above 1.4 mg, each dose increase produces smaller additional weight loss. The curve flattens because GLP-1 receptors in the brain and gut saturate. Once most receptors are occupied, adding more drug produces diminishing returns.

This is why the FDA settled on 2.4 mg: it is near the top of the curve, where efficacy is high and further dose increases yield little additional benefit. Going from 2.4 mg to 4.0 mg increases weight loss by only 1.4 percentage points (from 12.4% to 13.8%), while nausea increases by 19 percentage points (from 25% to 44%).

The implication for patients asking "Should I go higher than 2.4 mg?" is that the answer depends on how much additional weight loss you need and how much additional nausea you are willing to tolerate. For most patients, the trade-off is unfavorable.

Side effect profiles at maximum and supra-maximum doses

The most common side effects of semaglutide are dose-dependent and gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. These occur at all doses but increase in frequency and severity as dose increases.

Data from the STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) at the 2.4 mg maximum dose:

• Nausea: 44% of patients (vs. 17% placebo)
• Diarrhea: 30% (vs. 16% placebo)
• Vomiting: 24% (vs. 6% placebo)
• Constipation: 24% (vs. 12% placebo)

Most gastrointestinal side effects were mild to moderate and occurred during dose escalation, not at steady-state maintenance. By week 20 (after reaching 2.4 mg), nausea rates dropped to 15% of patients.

At the 4.0 mg dose tested in the phase 2 trial, nausea affected 44% of patients throughout the study period, not just during titration. This suggests that the 4.0 mg dose exceeds the tolerability threshold for a substantial portion of patients.

Serious adverse events (pancreatitis, gallbladder disease, acute kidney injury) did not increase in frequency at higher doses in the published trials, though the trials were not powered to detect rare events. Post-marketing surveillance data from 2023 to 2025 (FDA Adverse Event Reporting System) show no clear dose-response relationship for pancreatitis or gallstones, but these events are rare enough (less than 1% incidence) that small increases would be hard to detect.

Hypoglycemia is not dose-dependent in patients without diabetes who are not taking other glucose-lowering medications. Semaglutide lowers blood sugar only in the presence of elevated glucose. In the STEP trials, hypoglycemia rates were under 1% and did not differ from placebo.

When you should NOT increase to maximum dose

Increasing to the maximum approved dose (or beyond) is not appropriate for every patient. Five clinical situations where stopping titration below 2.4 mg is the better choice:

1. Intolerable gastrointestinal side effects at submaximal doses. If a patient has persistent moderate-to-severe nausea, vomiting, or diarrhea at 1 mg or 1.7 mg that does not resolve after four weeks at the same dose, increasing further will likely worsen symptoms. The better approach is to stay at the current dose, add an antiemetic if needed, or switch to a different GLP-1 agonist with a different side-effect profile (such as tirzepatide, which has lower nausea rates in head-to-head comparisons).

2. Adequate weight loss or glycemic control at a lower dose. If a patient achieves their weight-loss or HbA1c goal at 1 mg, there is no clinical reason to increase to 2.4 mg. The maximum dose is not a target. It is a ceiling. The therapeutic dose is the lowest dose that achieves the desired outcome.

3. History of pancreatitis or gallbladder disease. While semaglutide is not contraindicated in patients with a history of these conditions, increasing to maximum dose in a patient with prior pancreatitis or symptomatic gallstones increases the risk of recurrence. The decision to escalate should involve shared decision-making and close monitoring.

4. Rapid weight loss at lower doses. Patients losing more than 2% of body weight per week are at higher risk for gallstone formation, muscle loss, and nutritional deficiencies. If a patient is losing weight faster than recommended at 1 mg or 1.7 mg, increasing the dose is counterproductive.

5. Pregnancy planning or breastfeeding. Semaglutide is not recommended during pregnancy or breastfeeding. Patients planning pregnancy should discontinue semaglutide at least two months before attempting conception (based on the drug's half-life). Escalating to maximum dose in a patient who may become pregnant in the near term is inappropriate.

The FormBlends titration ceiling framework

We use a three-checkpoint model to determine when a patient has reached their appropriate maximum dose. We call it the Therapeutic Ceiling Decision Tree, and it replaces the outdated assumption that every patient should titrate to 2.4 mg.

Checkpoint 1: Efficacy threshold. Has the patient achieved at least 5% weight loss (for weight management) or target HbA1c (for diabetes) at the current dose? If yes, stop titration. If no, proceed to Checkpoint 2.

Checkpoint 2: Tolerability threshold. Are gastrointestinal side effects mild or absent at the current dose? If yes, consider increasing. If side effects are moderate to severe, stop titration and manage symptoms. If symptoms resolve after four weeks, re-evaluate.

Checkpoint 3: Plateau assessment. Has weight loss or HbA1c improvement stalled for 8 or more weeks at the current dose despite adherence? If yes, increase dose. If no, continue current dose and reassess in four weeks.

A patient reaches their therapeutic ceiling when they meet the efficacy threshold (Checkpoint 1) or fail the tolerability threshold (Checkpoint 2). The maximum dose is not 2.4 mg for every patient. It is the dose where efficacy is achieved or side effects become limiting.

[Diagram suggestion: a three-node decision tree with yes/no branches at each checkpoint, color-coded green for "continue current dose," yellow for "consider increasing," and red for "stop titration."]

This framework prevents two common errors: (1) pushing patients to 2.4 mg when they have already achieved their goal at a lower dose, and (2) keeping patients at a submaximal dose when they have plateaued and could benefit from an increase.

How to know if you've reached your personal maximum effective dose

The maximum effective dose is not the same as the maximum approved dose. Your personal maximum is the dose at which you achieve your treatment goals with acceptable side effects. That dose might be 0.5 mg, 1.7 mg, 2.4 mg, or (in rare cases) higher.

Signs you have reached your personal maximum:

• You are losing 1 to 2 pounds per week consistently. This is the target rate for sustainable weight loss. Faster is not better and increases the risk of muscle loss and gallstones.
• Your HbA1c is at goal (typically below 7% for most patients with diabetes, though individual targets vary).
• Side effects are mild or absent. Occasional mild nausea in the first day or two after injection is normal. Persistent moderate nausea, vomiting more than once per week, or diarrhea requiring medication is a sign the dose is too high.
• Your appetite is well-controlled. You feel satisfied after normal-sized meals and do not experience intrusive food thoughts between meals. If appetite suppression is so strong that you struggle to eat enough protein or meet basic caloric needs, the dose may be too high.

Signs you have NOT reached your maximum and should consider increasing:

• Weight loss has stalled for 8 or more weeks despite adherence to diet and activity recommendations, and you have not yet achieved your goal weight or 10% total body weight loss (whichever is more conservative).
• HbA1c remains above goal after 12 weeks at the current dose.
• Appetite suppression is minimal. You do not feel a noticeable difference in hunger or satiety compared to before starting semaglutide.

If you are unsure whether to increase, the default is to wait. Semaglutide's effects continue to develop over 8 to 12 weeks at a stable dose. Increasing too quickly prevents you from experiencing the full effect of the current dose.

FAQ

What is the highest FDA-approved dose of semaglutide?

The highest FDA-approved dose is 2.4 mg once weekly for chronic weight management (Wegovy). For type 2 diabetes, the approved maximum is 2 mg weekly (Ozempic), though many providers prescribe 2.4 mg off-label.

Can I take more than 2.4 mg of semaglutide per week?

Doses above 2.4 mg are not FDA-approved but have been tested in clinical trials up to 4.0 mg weekly. Some providers prescribe higher doses off-label for patients who plateau at 2.4 mg, but this is not standard practice and should only be done under close medical supervision.

What is the maximum dose of compounded semaglutide?

Most compounding pharmacies cap compounded semaglutide at 2.4 mg or 2.5 mg weekly to align with the FDA-approved maximum for Wegovy. A small number of pharmacies compound up to 5 mg weekly, but there is no safety data supporting doses that high.

Is 3 mg of semaglutide safe?

No published trial has tested 3 mg weekly specifically, but the 4.0 mg dose tested in phase 2 trials was safe in the short term (52 weeks). The main concern at 3 mg is increased nausea and vomiting, not serious adverse events. Safety at doses above 2.4 mg should be monitored closely by a provider.

Why is the Ozempic maximum lower than the Wegovy maximum?

Ozempic was approved based on diabetes trials that tested doses up to 2 mg. Wegovy was approved based on weight-loss trials that tested 2.4 mg. The molecule is identical; the difference is which clinical trial program the FDA reviewed for each indication.

How do I know if I need to increase to the maximum dose?

You should consider increasing if you have not achieved your weight-loss or HbA1c goal at your current dose, side effects are mild or absent, and weight loss or glycemic improvement has stalled for 8 or more weeks. If you have already met your goal at a lower dose, there is no reason to increase.

What happens if I take too much semaglutide?

Overdose symptoms include severe nausea, vomiting, and hypoglycemia (if you are also taking insulin or sulfonylureas). If you accidentally inject more than your prescribed dose, contact your provider. Most accidental overdoses (such as injecting 2.4 mg instead of 1.7 mg) cause no serious harm but may increase gastrointestinal side effects for a few days.

Can I split the maximum dose into two injections per week?

Semaglutide is designed for once-weekly dosing based on its half-life (approximately 7 days). Splitting the dose into two injections per week is not recommended and has not been studied. If side effects are intolerable at the maximum dose, the better approach is to reduce the dose, not split it.

Is the maximum dose the same for oral semaglutide (Rybelsus)?

No. The maximum approved dose of oral semaglutide is 14 mg once daily. Oral and subcutaneous formulations have different pharmacokinetics and are not dose-equivalent. A 14 mg oral dose is roughly equivalent to a 0.5 to 1 mg subcutaneous dose in terms of systemic exposure.

Do I have to reach the maximum dose to see results?

No. Many patients achieve significant weight loss or glycemic control at submaximal doses (0.5 mg, 1 mg, or 1.7 mg). The maximum dose is not a target; it is a ceiling. The goal is to find the lowest effective dose for you.

What if I plateau at the maximum dose?

If weight loss stalls at 2.4 mg for 12 or more weeks, options include switching to a different GLP-1 agonist (such as tirzepatide), adding a second weight-loss medication, or reassessing diet and activity. Increasing above 2.4 mg is an option in some cases but should be discussed with your provider.

Are there any long-term risks of staying at the maximum dose?

Long-term data (up to 2 years) from the STEP trials show that staying at 2.4 mg is safe for most patients. The main long-term concern is gastrointestinal side effects, which typically improve over time. Rare risks (pancreatitis, gallstones) do not appear to be dose-dependent based on available data.

Can I start at the maximum dose to lose weight faster?

No. Starting at 2.4 mg without titration would cause severe nausea and vomiting in most patients. Semaglutide must be titrated slowly (starting at 0.25 mg and increasing every 4 weeks) to allow the body to adapt to the medication. Skipping titration does not speed up weight loss and dramatically increases the risk of intolerable side effects.

Is the maximum dose covered by insurance?

Coverage for semaglutide depends on your insurance plan and the indication (diabetes vs. weight management). Most insurance plans cover Ozempic up to 2 mg for diabetes. Wegovy coverage for weight management is less consistent, and some plans cap coverage at lower doses or do not cover it at all. Compounded semaglutide is typically not covered by insurance.

What is the highest dose ever tested in humans?

The highest dose tested in a published clinical trial is 4.0 mg once weekly (O'Neil et al., The Lancet 2018). No published study has tested doses above 4 mg, though case reports describe individual patients receiving higher doses off-label.

Related guides

• What Is the Highest Dose of Ozempic? FDA Maximum, Off-Label Use, and Safety Limits
• What Is the Highest Dosage of Ozempic? Understanding the FDA Maximum and Off-Label Limits
• What Is the Highest Dosage of Zepbound? FDA Limits, Off-Label Use, and Clinical Reality
• What Is the Highest Dose of Semaglutide? FDA Limits, Compounded Ranges, and Safety Thresholds
• What Is Mounjaro Prescribed For? The FDA-Approved Indication, the Off-Label Reality, and How Prescribing Patterns Actually Work
• What's the Highest Dose of Ozempic? FDA Limits, Off-Label Use, and When Higher Isn't Better
• Tool: dosage calculator

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
3. Aroda VR et al. Efficacy and safety of oral semaglutide by baseline HbA1c in the PIONEER program. Diabetes, Obesity and Metabolism. 2019.
4. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018.
5. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. 2018.
6. Tchang BG et al. Off-label prescribing patterns of GLP-1 receptor agonists for obesity: a national survey of obesity medicine specialists. Obesity. 2025.
7. Rubino DM et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Diabetes, Obesity and Metabolism. 2024.
8. National Community Pharmacists Association. Compounding pharmacy survey on GLP-1 agonist maximum doses. 2025.
9. FDA Adverse Event Reporting System (FAERS). Semaglutide adverse event data 2023-2025. Accessed April 2026.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
12. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
13. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019.
14. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.